Program
Amiodarone
Also written as “Amiodarone Hydrochloride Tablets”, “Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs” and “amiodarone”.
Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Atrial Fibrillation, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Prism Pharmaceuticals | 20 open or running | phase 2since Aug 20, 2008 | Jan 8, 2007 | none ahead |
| Jemincare | 11 open or running | phase 1since Sep 12, 2025 | Sep 12, 2025 | none ahead |
| Johnson & Johnson | 10 open or running | phase 4since Oct 4, 2007 | Oct 4, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2007First study: phase 1 study in HealthyNew to Prism PharmaceuticalsPrism Pharmaceuticals · NCT00420953 · Canada
- Oct 4, 2007Johnson & Johnson's first study: phase 4 study in Atrial FibrillationNew to Johnson & JohnsonJohnson & Johnson · NCT00540787 · 112 enrolled · United States, France, Switzerland
- Aug 20, 2008Phase 2 study in Blood PressurePrism Pharmaceuticals · NCT00739193
- Sep 12, 2025Jemincare's first study: phase 1 study in Polycystic Kidney, Autosomal DominantNew to JemincareJemincare · NCT07181265 · 48 planned
TargetBeta
“HERG blocker”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07181265Polycystic Kidney, Autosomal Dominant | 1 | Not yet recruiting | Jemincare | Apr 30, 2026 | 48 |
| NCT00739193Blood Pressure | 2 | Withdrawn | Prism Pharmaceuticals | Dec 2008 | 0 |
| NCT00540787Atrial Fibrillation · United States, France, Switzerland | 4 | Completed | Johnson & Johnson | Jun 1, 2006 | 112 |
| NCT00420953Healthy · Canada | 1 | Completed | Prism Pharmaceuticals | Apr 23, 2007 |
How it is read
Names in the registry
- “Amiodarone Hydrochloride Tablets”, 1 entry
- “Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs”, 1 entry
- “amiodarone”, 1 entry
- “Cordarone”, 1 entry
Conditions, from the studies’ own filings
- Polycystic Kidney, Autosomal Dominant, 1 study
- Atrial Fibrillation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.